Author Archives: ev1

FDA hearing on stem cell therapy set on Friday, Aug. 23

Posted on by

By: Jet Villa, InterAksyon.com August 18, 2013 5:02 PM

REUTERS FILE PHOTO

InterAksyon.com The online news portal of TV5

MANILA, Philippines - The Food and Drug Administration (FDA) will conduct on Friday, August 23, a public hearing on the regulation of stem cell therapy in the country.

The FDA said the public hearing is scheduled from 3 p.m. to 5 p,m, at the Audio-Visual Room, 3rd floor, Annex Building, FDA office on Civil Drive in Alabang Muntinlupa.

The purpose of the hearing is to discuss the regulation of stem cell therapy, the stem cell products, and the health facilities that are offering the service in the court, it said.

The FDA also established an online reporting system to document adverse events linked to human cells, tissues, and cellular- and tissue-based products such stem cell therapies acquired in any facility.

The agency said those who experienced any untoward event or side effect or treatment failures after undergoing stem cell procedures can report through FDA website at http://www.fda.gov.ph under eReport and Adverse Drug Reaction, Report section.

E-mails may also be sent toreport@fda.gov.ph.

All consumers are assuredthat all information given will be treated with utmost confidentiality.Contact details are needed in case of a need for follow-up and validation.However, anonymous reports will still be accepted, the FDA added.

More:
FDA hearing on stem cell therapy set on Friday, Aug. 23

BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine …

Posted on by

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will give the keynote address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine conference on Monday, August 19, 2013, at 12:15 p.m. EDT in Cleveland, Ohio. Dr. West will discuss the potential use of embryonic mesenchymal progenitor cells, generated using BioTimes PureStemtechnology, in regenerative medicine and will contrast the properties of those cells with adult-derived mesenchymal stem cells. He will also discuss how those cells can be utilized in the search for genes potentially useful in induced tissue regeneration (iTR). The presentation will be available on BioTimes website at http://www.biotimeinc.com/scientific-presentations.

MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine, August 19-21, 2013, is being held at the Cleveland Marriott Downtown at Key Center and is presented by Case Western Reserve University and the National Center for Regenerative Medicine.

About BioTime, Inc

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

Read more from the original source:
BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine ...

Art of microbiology exhibit to open in Gallery90 at HAYC3

Posted on by

Monday August 19, 2013

HOOSICK FALLS, N.Y. -- Donna Maria de Creeft, the daughter of the world-renowned Hoosick Falls sculptor Jose de Creeft, will be showing a series of new works on paper, entitled, "Microbiology" in Gallery90 at the Hoosick Falls armory beginninning Aug. 23.

According to De Creeft, much of her work has been influenced by ideas and images gleaned from philosophy, anthropology, psychology, literature, mythology and science, especially chaos theory. However, she also attributes inspiration to her love of Hoosick Falls and the many summers she spent vacationing in the area as a child.

De Creefts exhibit will include a series of "Humanist Prayer Flags" and collages, which, she said, are based loosely on Tibetan prayer flags.

"Theyre like books with pages strung on linen thread," she said. "Each one is like a volume of mixed-media collages that incorporate photographs and illustrations of microscopic detail from scientific texts."

The components de Creeft created for the exhibit, which are drawn, painted, burnt and torn, relate visually to the found images.

The flags are "humanist," she says, "because they are about many of the things that make us human--our cells, our powers of observation, our relationship to the natural world, and our ability to rationally and irrationally make sense of our existence."

De Creefts artwork will be displayed in Gallery 90, located in the basement of the Hoosick Falls armory, between Aug. 23 and Sept. 20.

The opening reception, which is free and open to the public, will take place Friday, Aug. 23 from 6-8 p.m..

A concert by blues guitarist and vocalist Billy Gilbert will accompany the reception.

See original here:
Art of microbiology exhibit to open in Gallery90 at HAYC3

UMS researchers produce biofertiliser from oil palm empty fruit bunches

Posted on by

19th August, 2013

KOTA KINABALU: The Microbiology Research Group at the University Malaysia Sabah (UMS) Biotechnology Research Institute has developed a simple and easy way to produce biofertiliser from oil palm fibre empty fruit bunches (EFB) within 40 days.

Its senior researcher Dr Md Shafiquzzaman Siddiquee and his postgraduate student, Nur Shafawati Saili, had conducted the research on converting oil palm industry waste to the biofertiliser.

The application of biofertiliser in nursery and field trials found among others, successful enhancement of plant growth, root development, an increase in plant branches, inflorescences and yield production.

Huge amounts of waste products are creating lots of environmental problems and ecosystem degradation, while affecting the health of communities, with high disposal costs annually, Md Shafiquzzaman told Bernama, here.

He said composting was an alternative way of transforming the bulky biomass into a valuable, manageable product, for use on plantations or as a market product.

In this respect, the production of palm oil is a key agricultural activity in Malaysia, and the country has become a top producer of the product in the world, while drawing large revenue from it.

Malaysia oil palm plantations account for about 41 per cent of the worlds palm oil production and occupy 4.5 million hectares of land. Oil palm fibres (trunks, fronds and empty fruit bunches) are considered major waste products, he added.

He said using the species specific-strain of Trichoderma in composting has widened, not only as a biological control agent but for accelerating rapid composting, the control of plant diseases, a strong competitive effect on space and nutrients, the ability to degrade woody materials, while increasing the production yield, and as biocontrol, biopesticides, bioherbicides, enzyme and toxin producers.

Md Shafiquzzaman said the specific-strain of Trichoderma used as a biofertiliser had many superior properties to that of the powder-based products presently available in the market.

The rest is here:
UMS researchers produce biofertiliser from oil palm empty fruit bunches

American Academy of Anti-Aging Medicine (A4M) ABAARM Board Certification Overview – Video

Posted on by


American Academy of Anti-Aging Medicine (A4M) ABAARM Board Certification Overview
The American Academy of Anti-Aging Medicine (A4M) provides Board Certification to physicians and healthcare practitioners through its ABAARM and ABAAHP progr...

By: A4MEvents

Follow this link:
American Academy of Anti-Aging Medicine (A4M) ABAARM Board Certification Overview - Video

Consultant quits over DOH chief’s stand on stem cell therapy

Posted on by

By: Jet Villa, InterAksyon.com August 16, 2013 8:24 AM

InterAksyon.com The online news portal of TV5

MANILA, Philippines -- (UPDATE - 10:12 a.m.) A consultant of Secretary Enrique Ona resigned Friday, calling the Health chiefs position that patients undergoing experimental stem cell therapy should pay unacceptable.

Dr. Anthony Leachon, who is in Davao City, said he emailed his resignation letter to Ona.

It is with deep regret that I'm resigning asDepartment of Health consultant for non-communicable diseases effective today (Friday). I have been privileged and honored to be a part of your administration even as a one peso a year consultant. I value our friendship and camaraderie which started years ago, Leachon, vice president of the Philippine College of Physicians and Onas consultant for non-communicable diseases, wrote.

Because his position is directly opposed to Onas, Leachon told the Health secretary, I believe I have lost your trust and confidence and I might not be effective serving the DOH and fighting the PCP and medical societies ' cause in the service of the Filipino patient.

Leachon was Onas consultant for non-communicable diseases since November 2011.

Ang pinaka-hindi ko nagustuhan ay yung sisingilin ang pasyente kahit clinical trial pa lang. Yon ang unacceptable sa akin (What I disagree with most is charging patients even if what they undergo are just clinical trials. That is unacceptable), Leachon said.

His resignation came as the National Health Institute, the research arm for health sciences of the University of the Philippines-Manila, joined the growing opposition to the Health secretarys stand on experimental stem cell therapy.

Leachon, a cardiologist at the Manila Doctors Hospital, called Onas position a complete violation of the Code of Ethics (for doctors) and being the secretary of health, alam niya dapat yon (he should know that). This is not a sign of ignorance, pero siguro may mga taong iba ang sinasabi sa kaniya (but there may be people telling him otherwise).

Read more:
Consultant quits over DOH chief's stand on stem cell therapy